Psoriasis research hub

A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging study of Efficacy and Safety of SAR441566 in Adults with Moderate to Severe Plaque Psoriasis

This study is testing a new medicine called SAR441566 for moderate to severe plaque psoriasis. Researchers want to see if it helps improve psoriasis symptoms and if it's safe. It's a key step to understand if this medicine could become a future treatment option.

HIPPOCRATES Prospective Observational Study

This study aims to find out why some people with psoriasis get psoriatic arthritis. We'll use questionnaires and some blood samples to help identify those at risk. Our goal is to one day prevent arthritis from developing.

SEquential Treatment of PSoriasis With Biologics

This study looks at how well different psoriasis treatments called biologics work when people try several in a row. It uses existing health records to understand if these treatments become less effective over time. No extra appointments are needed for this research.

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

This study looks at the long-term safety of ustekinumab in children and teenagers (6-17) with moderate to severe plaque psoriasis. Researchers will monitor for serious infections, cancers, and autoimmune issues, as well as checking the drug's effects on growth and development.

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

This study looks at a medicine called risankizumab for children aged 6 to 17 with moderate to severe psoriasis. It checks for side effects and how well the medicine works in those who were part of an earlier study. Risankizumab is already used for adults with psoriasis.

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

This study looks at the everyday safety and effectiveness of a new medicine, deucravacitinib, for people with psoriasis who have been in previous studies. It also checks how the body responds to common vaccines while taking this medicine.

Walk and Talk: Connecting People With Psoriasis

This study looks at creating 'Walk and Talk' groups for people with psoriasis. It aims to see if these groups help improve social connections, physical activity, and overall wellbeing, and how best to run them.

Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema

This study is looking at a new cream, RLS-1496, for people who have psoriasis or eczema. It's the very first time this cream is being tested in humans to see if it's safe and how it works. We want to understand if it could help these skin conditions.

A Phase 4 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Psoriasis

This study looks at how an early treatment for moderate to severe psoriasis, called Skyrizi, affects certain cells in the skin. Researchers want to see if starting treatment sooner helps reduce these cells more effectively than starting later, and how clear the skin becomes.

A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants

This study is looking at how a new medicine for psoriasis is taken up by the body and if food changes this. It's for healthy volunteers to help us understand the medicine better before it's given to people with psoriasis.

A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study)